Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This study in healthy volunteers aims to demonstrate similar PK and PD properties of the new
human biphasic insulin, Julphar Insulin 30/70 and an already approved reference insulin,
Huminsulin® Profil III. All participants will receive both study treatments on two separate
dosing days.